Evolus (EOLS) Stock Price, News & Analysis

Company Overview

Evolus, Inc. is a medical aesthetics company focused on developing and commercializing products for healthcare professionals and consumers. The company’s business is centered on aesthetic treatments designed to address facial lines, wrinkles, skin quality and other signs of aging.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines.” The company markets Jeuveau through its physician-focused Evolus Aesthetic Center platform and related digital tools, education and patient-engagement services.

The company has expanded beyond neuromodulators into dermal fillers and other aesthetic products, including its Evolysse hyaluronic acid filler portfolio. Evolus primarily serves aesthetic physicians, dermatologists, plastic surgeons and medical spas, with commercial operations focused on the United States and an expanding international presence. The company is headquartered in Newport Beach, California, and is led by Chief Executive Officer David Moatazedi.

Key Stats

• Today's Range: $6.91 to $7.72
• 50-Day Range: $5.84 to $9.30
• 52-Week Range: $3.86 to $9.31
• Volume: 2.07 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $471.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Moderate Buy

Evolus Stock Analysis - MarketRank™

Evolus scored higher than 51% of companies evaluated by MarketBeat, and ranked 545th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Evolus has a consensus price target of $14.50, representing about 102.4% upside from its current price of $7.17.

Amount of Analyst Coverage

Evolus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evolus are expected to grow in the coming year, from ($0.36) to $0.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolus is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolus is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.81% of the float of Evolus has been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Evolus has recently increased by 3.01%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolus does not currently pay a dividend.

Dividend Growth

Evolus does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.92

News Sentiment

Evolus has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Evolus this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $950,176.00 in company stock.

Percentage Held by Insiders

5.00% of the stock of Evolus is held by insiders.

Percentage Held by Institutions

90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:EOLS
• CIK: 1570562
• Web: www.evolus.com
• Phone: (949) 284-4555
• Fax: N/A
• Employees: 353
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Evolus: $14.50
• High Price Target: $17.00
• Low Price Target: $13.00
• Potential Upside/Downside: +103.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.64 million
• Net Margins: -10.85%
• Pretax Margin: -10.64%
• Return on Equity: N/A
• Return on Assets: -13.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.70
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $297.18 million
• Price / Sales: 1.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.36) per share
• Price / Book: -19.82

Miscellaneous

• Outstanding Shares: 66,050,000
• Free Float: 62,748,000
• Market Cap: $471.27 million
• Optionable: Optionable
• Beta: 1.34